Teva Pharmaceuticals Reports Successful Clinical Trial for Celiac Disease Antibody
Translated & summarized from Kan News by baba
Teva Pharmaceuticals announced positive results from a Phase 1 trial of its experimental antibody TEV'408 for celiac disease, which successfully prevented gluten-induced intestinal damage in adult patients. The drug is also being developed for vitiligo and has received fast-track designation from the FDA for celiac disease.
The story in 5 lines · by baba
- Teva's antibody TEV'408 successfully prevented gluten-induced intestinal damage in celiac patients.
- The trial met its primary endpoint, showing statistically significant and clinically meaningful results.
- The experimental drug targets the IL-15 protein involved in inflammatory pathways.
- Teva is also developing TEV'408 for vitiligo and received FDA fast-track designation for celiac disease.
- Celiac disease affects 1% of the population, with no current approved drug treatments.
Teva Pharmaceuticals announced on Wednesday positive results from a clinical trial of its novel antibody for celiac disease in adults. The company stated that the trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prevention of intestinal damage caused by gluten exposure. The study involved 50 adult patients diagnosed with the condition.
The experimental antibody, known as TEV'408, works by inhibiting the activity of IL-15, a protein implicated in inflammatory and immune pathways. Teva is developing this drug for both celiac disease and vitiligo.
In May 2025, the U.S. Food and Drug Administration granted TEV'408 fast-track designation for the treatment of celiac disease. Development for vitiligo is also progressing, with the program expected to advance to Phase 2b following encouraging preliminary results.
Celiac disease is a chronic autoimmune disorder where gluten consumption leads to damage in the small intestine. Affecting approximately 1% of the global population, there is currently no approved drug treatment. While a gluten-free diet is the standard management, many patients continue to experience symptoms, reduced quality of life, and ongoing intestinal damage, highlighting the need for new therapeutic options.
